Predictors of sustained reverse remodelling in patients with heart failure with reduced ejection fraction

被引:0
|
作者
Furquim, Silas Ramos [1 ]
Bocchi, Edimar Alcides [1 ]
Lira, Maria Tereza Sampaio de Sousa [1 ]
Wanderley Jr, Mauro Rogerio de Barros [2 ]
de Marchi, Daniel Catto [1 ]
Maciel, Pamela Camara [1 ]
Zimerman, Andre [3 ]
Ramires, Felix Jose Alvarez [1 ]
Nastari, Luciano [1 ]
Biselli, Bruno [1 ]
Chizzola, Paulo Roberto [1 ]
Munhoz, Robinson Tadeu [1 ]
Fernandes, Fabio [1 ]
Ayub-Ferreira, Silvia Moreira [1 ]
机构
[1] Univ Sao Paulo, Hosp Clin HCFMUSP, Fac Med, Inst Coracao InCor, Sao Paulo, SP, Brazil
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, EUA, Boston, MA USA
[3] Hosp Moinhos Vento, Moinhos Vento Coll Hlth Sci, Clin Trials Unit, Porto Alegre, Brazil
来源
关键词
heart failure with reduced ejection fraction; reverse remodelling; sustained reverse remodelling; DILATED CARDIOMYOPATHY; OUTCOMES;
D O I
10.1002/ehf2.15241
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Patients with heart failure with reduced ejection fraction (HFrEF) who achieve reverse remodelling (RR) can experience a new decrease in ejection fraction (EF), and the predictors of sustained RR (SRR) are not completely understood. Objectives The study aims to identify predictors of SRR in patients with HFrEF after an increase in EF and evaluate SRR prognosis. Methods In this retrospective, observational study, we evaluated a real-life cohort of patients with HFrEF and >= 2 consecutive echocardiograms, divided according to left ventricular EF (LVEF) trajectory: no RR (NRR: 3/3 LVEF measurements < 40%), non-SRR (NSRR: second LVEF >= 40%, third LVEF < 40%), and SRR (SRR: second and third LVEF >= 40%). Results We included 3628 of 8072 assessed HF patients in the analysis, with mean age 56.2 (+/- 13.4) years, 64.4% male and 77.7% New York Heart Association (NYHA) I-II. Improved EF was observed for 1342 (37%) patients. Among those who achieved RR, 310 (23%) were NSRR, and 1032 (77%) were SRR. The mean (+/- SE) survival after the second echocardiogram was 10.6 (+/- 0.2) years. The SRR group had the longest survival (12.2 +/- 0.3 years), followed by the NSRR (10.6 +/- 0.5) and NRR (9.8 +/- 0.2 years) groups (P < 0.001). According to logistic multivariable regression, second LVEF [odds ratio (OR) = 1.06, confidence interval (CI) = 1.03-1.90, P < 0.001], second left ventricular end-systolic diameter (LVESD) (OR = 0.93, CI = 0.90-0.96, P < 0.001), second IV septum thickness (OR = 1.12, CI = 1.03-1.23, P = 0.012), systolic blood pressure (OR = 1.01, CI = 1.00-1.02, P = 0.014), NYHA I-II (OR = 1.86, CI = 1.27-2.74, P = 0.001) and furosemide non-use (OR = 1.87, CI = 1.27-2.74, P < 0.001) independently predicted SRR. Conclusions Patients with greater EF increases and LVESD reductions at EF recovery, greater septum thickness, higher blood pressure, no need for diuretics and NYHA I/II maintenance had the best chance of maintaining recovered ventricular function.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Reverse remodelling and clinical outcomes in patients with chagas cardiomyopathy with reduced ejection fraction
    Lira, M. Sampaio De Sousa
    Furquim, S. F. Silas
    De Marchi, D. C. M. Daniel Catto
    Maciel, P. C. M. Pamela Camara
    Dantas, R. D. Rafael
    Fernandes, F. F. Fabio
    Ianni, B. M. I. Barbara Maria
    Ferreira, S. M. A. F. Silvia Moreira Ayub
    Lima, E. G. L. Eduardo Gomes
    Bocchi, E. A. B. Edimar Alcides
    EUROPEAN HEART JOURNAL, 2024, 45
  • [22] Echocardiographic predictors of exercise intolerance in patients with heart failure with severely reduced ejection fraction
    Zaborska, Beata
    Smarz, Krzysztof
    Makowska, Ewa
    Czepiel, Aleksandra
    Swiatkowski, Maciej
    Jaxa-Chamiec, Tomasz
    Budaj, Andrzej
    MEDICINE, 2018, 97 (28)
  • [23] Left ventricular reverse remodelling and prognosis of patients treated with SGLT2 inhibitors for heart failure with reduced ejection fraction.
    Tinoco, M. Mariana
    Cardoso, F.
    Dias, G.
    Pereira, T.
    Faria, B.
    Almeida, F.
    Leite, S.
    Lourenco, A.
    EUROPEAN JOURNAL OF HEART FAILURE, 2022, 24 : 58 - 58
  • [24] Dapagliflozin for patients with heart failure and reduced ejection fraction
    Ferry, Abigail
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2022, 35 (09): : 51 - 53
  • [25] Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
    McMurray, J. J. V.
    Solomon, S. D.
    Inzucchi, S. E.
    Kober, L.
    Kosiborod, M. N.
    Martinez, F. A.
    Ponikowski, P.
    Sabatine, M. S.
    Anand, I. S.
    Belohlavek, J.
    Bohm, M.
    Chiang, C. -E.
    Chopra, V. K.
    de Boer, R. A.
    Desai, A. S.
    Diez, M.
    Drozdz, J.
    Dukat, A.
    Ge, J.
    Howlett, J. G.
    Katova, T.
    Kitakaze, M.
    Ljungman, C. E. A.
    Merkely, B.
    Nicolau, J. C.
    O'Meara, E.
    Petrie, M. C.
    Vinh, P. N.
    Schou, M.
    Tereshchenko, S.
    Verma, S.
    Held, C.
    DeMets, D. L.
    Docherty, K. F.
    Jhund, P. S.
    Bengtsson, O.
    Sjostrand, M.
    Langkilde, A. -M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21): : 1995 - 2008
  • [26] Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Armstrong, Paul W.
    Pieske, Burkert
    Anstrom, Kevin J.
    Ezekowitz, Justin
    Hernandez, Adrian F.
    Butler, Javed
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Voors, Adriaan A.
    Jia, Gang
    McNulty, Steven E.
    Patel, Mahesh J.
    Roessig, Lothar
    Koglin, Joerg
    O'Connor, Christopher M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20): : 1883 - 1893
  • [27] Dapagliflozin in patients with heart failure and reduced ejection fraction
    Giorgio Colombo
    Rosa Casella
    Alessia Cazzaniga
    Chiara Casiraghi
    Internal and Emergency Medicine, 2020, 15 : 515 - 517
  • [28] Hypertension in Patients with Heart Failure with Reduced Ejection Fraction
    Volpe, Massimo
    Santolamazza, Caterina
    Tocci, Giuliano
    CURRENT CARDIOLOGY REPORTS, 2016, 18 (12)
  • [29] Cells in Patients with Heart Failure with Reduced Ejection Fraction
    Lopes, Jose
    Teixeira, Manuel
    Cavalcante, Suiane
    Gouveia, Marisol
    Duarte, Ana
    Ferreira, Miriam
    Simoes, Maria I.
    Conceicao, Maria
    Ribeiro, Ilda P.
    Goncalves, Ana C.
    Schmidt, Cristine
    de Jesus, Bruno Bernardes
    Almeida, Ramiro
    Viamonte, Sofia
    Santos, Mario
    Ribeiro, Fernando
    ARCHIVES OF MEDICAL RESEARCH, 2022, 53 (03) : 289 - 295
  • [30] Dapagliflozin in patients with heart failure and reduced ejection fraction
    Colombo, Giorgio
    Casella, Rosa
    Cazzaniga, Alessia
    Casiraghi, Chiara
    INTERNAL AND EMERGENCY MEDICINE, 2020, 15 (03) : 515 - 517